Terminal functionalized thiourea-containing dipeptides as multidrug-resistance reversers that target 20S proteasome and cell proliferation.

A series of inhibitors of 20S proteasome based on terminal functionalized dipeptide derivatives containing the thiourea moiety were synthesized and evaluated for inhibition of 20S proteasome and the effects of multidrug-resistance reversers. These compounds exhibited significant selectivity to the β5-subunit of the human 20S proteasome with IC50 values at submicromolar concentrations. A docking study of the most active compound 6i revealed key interactions between 6i and the active site of the 20S proteasome in which the thiourea moiety and a nitro group were important for improving activity. In particular, compound 6i appeared to be the most potent compound against the NCI-H460 cell line, and displayed similar efficiency in drug-sensitive versus drug-resistant cancer cell lines, at least partly, by inhibition of the activity of 20S proteasome and induce apoptosis. In addition, 6i-induced apoptosis was significantly facilitated in NCI-H460/DOX cells that had been pretreated with inhibitors of P-gp. Mechanistically, compound 6i might trigger apoptotic signalling pathway. Thus, we conclude that dipeptide derivatives containing the thiourea moiety may be the potential inhibitors of proteasome with the ability to reverse multidrug resistance.

[1]  E. Jacobsen,et al.  Small-Molecule H-Bond Donors in Asymmetric Catalysis , 2008 .

[2]  P. Richardson,et al.  Bortezomib: proteasome inhibition as an effective anticancer therapy. , 2005, Future oncology.

[3]  Y. Piao,et al.  Zinc ribbon domain-containing 1 (ZNRD1) mediates multidrug resistance of leukemia cells through regulation of P-glycoprotein and Bcl-2 , 2005, Molecular Cancer Therapeutics.

[4]  Carlos Alemán,et al.  On the Ability of Modified Peptide Links to Form Hydrogen Bonds , 2001 .

[5]  S. Hecht,et al.  Synthesis of a new class of bis(thiourea)hydrazide pseudopeptides as potential inhibitors of β-sheet aggregation. , 2012, Organic letters.

[6]  S Iida,et al.  Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress , 2010, Leukemia.

[7]  Richard Pazdur,et al.  Bortezomib for the Treatment of Mantle Cell Lymphoma , 2007, Clinical Cancer Research.

[8]  M. Leippe,et al.  Novel peptidomimetics containing a vinyl ester moiety as highly potent and selective falcipain-2 inhibitors. , 2009, Journal of medicinal chemistry.

[9]  James Lowe,et al.  Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets , 2010, Nature Reviews Drug Discovery.

[10]  M. Rolfe,et al.  Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. , 2010, Cancer research.

[11]  Ri-zhen Huang,et al.  Synthesis and pharmacological evaluation of dehydroabietic acid thiourea derivatives containing bisphosphonate moiety as an inducer of apoptosis. , 2016, European journal of medicinal chemistry.

[12]  H. Yamaguchi,et al.  Bax plays a pivotal role in thapsigargin-induced apoptosis of human colon cancer HCT116 cells by controlling Smac/Diablo and Omi/HtrA2 release from mitochondria. , 2003, Cancer research.

[13]  Marianne Fillet,et al.  NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells , 2003, Oncogene.

[14]  M. Groll,et al.  20S Proteasome and Its Inhibitors: Crystallographic Knowledge for Drug Development , 2007 .

[15]  James B Lorens,et al.  Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. , 2009, Blood.

[16]  S. M. Gomha,et al.  A facile one-pot synthesis of 6,7,8,9-tetrahydrobenzo[4,5]thieno[2,3-d]-1,2,4-triazolo[4,5-a]pyrimidin-5-ones , 2009 .

[17]  L. Pfeffer,et al.  Interferon Induces NF-κB-inducing Kinase/Tumor Necrosis Factor Receptor-associated Factor-dependent NF-κB Activation to Promote Cell Survival* , 2005, Journal of Biological Chemistry.

[18]  T. Schirmeister,et al.  Development of Novel Peptidomimetics Containing a Vinyl Sulfone Moiety as Proteasome Inhibitors , 2011, ChemMedChem.

[19]  R. Huber,et al.  Inhibitor-binding mode of homobelactosin C to proteasomes: new insights into class I MHC ligand generation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Goldberg,et al.  Importance of the Different Proteolytic Sites of the Proteasome and the Efficacy of Inhibitors Varies with the Protein Substrate* , 2006, Journal of Biological Chemistry.

[21]  Afshin Samali,et al.  Mediators of endoplasmic reticulum stress‐induced apoptosis , 2006, EMBO reports.

[22]  Pinaki S. Bhadury,et al.  Synthesis and in vitro study of pseudo-peptide thioureas containing α-aminophosphonate moiety as potential antitumor agents. , 2010, European journal of medicinal chemistry.

[23]  Xiaoyong Xu,et al.  Facile and Versatile Synthesis of Alkyl and Aryl Isothiocyanates by Using Triphosgene and Cosolvent. , 2014 .

[24]  E. Novellino,et al.  Development of peptidomimetic boronates as proteasome inhibitors. , 2013, European journal of medicinal chemistry.

[25]  G. Giaccone,et al.  Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies , 2005, Cancer.

[26]  K. Anderson,et al.  Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. , 2003, Blood.

[27]  Cun-Yu Wang,et al.  Proteasome Inhibitor PS-341 Induces Apoptosis through Induction of Endoplasmic Reticulum Stress-Reactive Oxygen Species in Head and Neck Squamous Cell Carcinoma Cells , 2004, Molecular and Cellular Biology.

[28]  J. Friedberg,et al.  BCL-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress , 2009, Cancer biology & therapy.

[29]  E. Novellino,et al.  Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors. , 2014, European journal of medicinal chemistry.

[30]  藤田 武郎.  Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance , 2005 .

[31]  Shiv k. Sharma,et al.  (Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators. , 2010, Journal of medicinal chemistry.

[32]  D. McConkey,et al.  Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. , 2005, Cancer research.

[33]  Matthew Britton,et al.  Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites. , 2009, Chemistry & biology.

[34]  J. Yadav,et al.  A novel trifunctional organocatalyst for the asymmetric aldol reaction: a facile enantioselective synthesis of β-hydroxyketones , 2011 .